Media coverage about IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) has been trending somewhat negative on Tuesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. IntelliPharmaCeutics Intl earned a media sentiment score of 0.00 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.5524968718093 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
IPCI has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of IntelliPharmaCeutics Intl from a “sell” rating to a “hold” rating in a research note on Wednesday, December 13th. HC Wainwright set a $3.00 target price on shares of IntelliPharmaCeutics Intl and gave the stock a “buy” rating in a research note on Monday, March 5th. Finally, Maxim Group lowered shares of IntelliPharmaCeutics Intl from a “buy” rating to a “hold” rating in a research note on Friday, February 16th. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $2.53.
IntelliPharmaCeutics Intl (NASDAQ:IPCI) remained flat at $$0.62 during trading on Tuesday. The stock had a trading volume of 886,658 shares, compared to its average volume of 418,918. IntelliPharmaCeutics Intl has a twelve month low of $0.51 and a twelve month high of $2.92. The company has a market capitalization of $26.71, a price-to-earnings ratio of -2.14 and a beta of 1.23.
IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) last posted its quarterly earnings data on Friday, February 16th. The company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.01). IntelliPharmaCeutics Intl had a negative return on equity of 2,811.75% and a negative net margin of 160.89%. The business had revenue of $1.08 million for the quarter, compared to analyst estimates of $1.32 million. equities analysts anticipate that IntelliPharmaCeutics Intl will post -0.18 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.thestockobserver.com/2018/03/20/intellipharmaceutics-intl-ipci-receiving-somewhat-critical-press-coverage-accern-reports.html.
IntelliPharmaCeutics Intl Company Profile
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.